AtaGenix Laboratories
AtaGenix Laboratories
With 15+ years of expertise and 1,500+ proteins produced, AtaGenix excels in custom protein expression across five optimized platforms. We offer small to large-scale protein production, from gene synthesis to bioreactor-scale expression, with custom solutions for parallel condition screening and extended optimization.
Our high-throughput screening tackles challenges in solubility, purity, functionality, and productivity, ensuring optimal expression of antibodies, enzymes, membrane proteins, and cytokines. Backed by cutting-edge protein engineering technology, AtaGenix delivers reliable, scalable, and high-yield recombinant protein production.
A 2017 study developed a high-affinity anti-HE4 monoclonal antibody (9C3) using AtaGenix’s advanced mammalian expression and hybridoma platforms. This breakthrough enhances ovarian cancer diagnostics by targeting the HE4 biomarker with high specificity, offering potential for early detection and therapy.
This article highlights a 2021 Small Methods study that identified immunogenic peptides in the SARS-CoV-2 spike protein and isolated neutralizing monoclonal antibodies from COVID-19 patients. The research pinpointed key RBM epitopes (S431-454, S470-486, S501-515), with S470-486 emerging as an immunodominant target for diagnostics and therapeutics. Using phage display and ScFv libraries, the study validated epitope mapping and antibody functionality. Supported by AtaGenix’s expertise in phage display, protein expression, and assay development, this breakthrough offers a scalable approach for combating emerging viral pathogens, updated as of August 24, 2025.
Contact Us
+86-27-87001869
info@atagenix.com
Building C, R & D Building, No. 666, Shendun 4th Road, Donghu New Technology Development Zone, Wuhan
